Nuvectis Pharma Inc.

NVCT | NASDAQ

Price Alert Chart Builder DCF Calculator

$21.98

-$0.02 (-0.09%)

At close: Sep 21, 2026, 4:00 PM ET

$21.98

$0 (0.00%)

After-hours: Sep 21, 2026, 4:10 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Key Executives

Name	Position
Ron Bentsur	Co-Founder, Chairman, Chief Executive Officer & President
Enrique Poradosu	Co-Founder, Executive Vice President, Chief Scientific & Business Officer
Michael Carson	Vice President of Finance
Shay Shemesh	Co-Founder, Executive Vice President, Chief Development & Operations Officer

Latest SEC Filings

Date	Type	Title
Aug 28, 2026	EFFECT	Filing
Aug 21, 2026	S-3	Filing
Aug 21, 2026	8-K	Current Report
Aug 06, 2026	SC 13G	Statement of acquisition of beneficial ownership b...
Aug 05, 2026	4	Filing
Aug 04, 2026	10-Q	Quarterly Report
Aug 04, 2026	8-K	Current Report
Jul 01, 2026	4	Filing
Jul 01, 2026	4	Filing
Jun 30, 2026	8-K	Current Report

View All SEC Filings ➞

Nuvectis Pharma Inc.

Country	United States
IPO Date	Feb 3, 2022
Industry	Biotechnology
Sector	Healthcare
Employees	16
CEO	Ron Bentsur

Contact Details

1 Bridge Plaza Fort Lee, New Jersey 07024 United States

https://www.nuvectis.com

201 614 3150

Stock Details

Ticker Symbol	NVCT
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001875558
CUSIP Number	67080T108
ISIN Number	US67080T1088
SIC Code	2834